CG
PRLD icon

Cutler Group’s Prelude Therapeutics PRLD Stock Holding History

Cutler Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-130
Closed – – 4180
2023
Q3 		$0 Hold
130
– – ﹤0.01% 4217
2023
Q2 		$0 Sell
130
-2,000
-94% -$11.9K ﹤0.01% 4049
2023
Q1 		$12K Hold
2,130
– – ﹤0.01% 2225
2022
Q4 		$12K Buy
+2,130
New +$13.6K ﹤0.01% 2588
2022
Q3 		– Sell
-100
Closed – – 5371
2022
Q2 		$0 Hold
100
– – ﹤0.01% 5510
2022
Q1 		$0 Buy
+100
New +$915 ﹤0.01% 5873

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's PRLD Position: Q4 2023 in Review

Cutler Group sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 130 shares.

Cutler Group first reported a position in PRLD in Q1 2022 and held it in 6 quarters. The position peaked at $12K in Q1 2023. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

  • Cutler Group reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 130 Prelude Therapeutics shares in Q4 2023.
  • Cutler Group first reported a position in Prelude Therapeutics in Q1 2022 and held it in 6 quarters.
  • Cutler Group's Prelude Therapeutics position peaked at $12K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.